Last reviewed · How we verify
placebo of warfarin
placebo of warfarin is a Small molecule drug developed by University Hospital, Brest. It is currently in Phase 3 development for Control arm in warfarin efficacy and safety trial (indication under investigation).
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and physiological expectation.
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and physiological expectation. Used for Control arm in warfarin efficacy and safety trial (indication under investigation).
At a glance
| Generic name | placebo of warfarin |
|---|---|
| Sponsor | University Hospital, Brest |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to measure the effect of patient expectation and the natural disease course independent of active drug treatment. In this Phase 3 trial context, the placebo serves as a comparator arm against warfarin, a vitamin K antagonist anticoagulant. Any observed effects in the placebo group reflect the placebo effect, regression to the mean, and natural disease progression rather than direct molecular action.
Approved indications
- Control arm in warfarin efficacy and safety trial (indication under investigation)
Common side effects
Key clinical trials
- Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects (PHASE1)
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation (EARLY_PHASE1)
- Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI) (PHASE3)
- BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam (PHASE1)
- Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy (PHASE4)
- PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin. (PHASE3)
- A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects (PHASE1)
- Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo of warfarin CI brief — competitive landscape report
- placebo of warfarin updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI
Frequently asked questions about placebo of warfarin
What is placebo of warfarin?
How does placebo of warfarin work?
What is placebo of warfarin used for?
Who makes placebo of warfarin?
What development phase is placebo of warfarin in?
Related
- Manufacturer: University Hospital, Brest — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Control arm in warfarin efficacy and safety trial (indication under investigation)
- Compare: placebo of warfarin vs similar drugs
- Pricing: placebo of warfarin cost, discount & access